Organogenesis launches new sizing option for PuraPly wound care device

MIT-spinoff Organogenesis announced today that its PuraPly antimicrobial wound care device is now available in a 1.6-cm disc size.

The Canton, Mass.-based company’s PuraPly AM product includes a broad-spectrum antibiotic, polyhexamethylene biguanide, embedded into a purified native collagen matrix. The device is cleared to treat an array of wound types, including pressure ulcers, surgical wounds, trauma wounds and diabetic ulcers.

“A vast majority of wounds – including small ones – contain biofilm, which represents a serious challenge to wound healing,” Gary Gillheeney, Sr., president & CEO, said in prepared remarks. “The new small size of PuraPly AM – which utilizes PHMB to manage bioburden while supporting healing – gives clinicians an exciting new option for treating a wide range of small wounds.”

In March last year, Organogenesis acquired NuTech Medical for an undisclosed price. The deal combined Organogenesis’ wound care products with NuTech’s surgical biologics.

The company also launched a clinical trial program last year for its PuraPly AM device, evaluating the product as an antimicrobial wound management therapy, as well as its ability to manage bioburden, support granulation tissue formation and support wound closure.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW